Cquence
Pan-Heme Panel

Test type

NGS panel test

Background

Cquence Pan-Heme Panel delivers information on predictive and prognostic mutations which are commonly involved in hematolymphoid malignancies and precursor lesions such as acute myelogenous, lymphoid leukemias, myelodysplasias, myeloproliferative disorders and lymphomas. It is designed to classify hemato-lymphoid neoplasms in a molecular level, which is important to determine the prognosis and predict the response to targeted and/or non-targeted therapy. The panel has a sensitivity of ~5 % mutant allele with strict next generation sequencing quality control parameters.

Test specifications

Test code	Methodology	Specimen requirements	Turnaround time
OKH	Next-generation sequencing supplemented with Sanger sequencing	6 mL blood in EDTA tube	10-14 days

Genes targeted (73 genes)

1D3, ABL1, ASXL1, ATM, BCL2, BCL6, BCOR, BIRC3, BRAF, CALR, CARD11, CBL, CBL-B, CCND1, CD79A, CDKN2A, CEBPA, CREBBP, CSF3R, DNMT3A, EP300, ETV6, EZH2, FAM5C, FBXW7, FLT3, FOXO1, GATA1, GATA2, GNA13, HNRNPK, HRAS, IDH1, IDH2, IKZF1, IL7R, JAK1, JAK2, JAK3, KDM6A/UTX, KIT, KRAS, MEF2B, MLL, MLL2, MPL, MYC, MYD88, NOTCH1, NOTCH2, NPM1, NRAS, PAX5, PHF6, PRDM1, PTEN, PTPN11, RAD21, RUNX1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, STAT3, SUZ12, TDF3, TET, TNFAIP3, TNFRSF14, U2AF35, WT1 and *ZRSR2*